BACKGROUND: In patients over age 60 with acute myeloid leukemia (AML), cure rates are under 10% despite intensive chemotherapy. These patients often have comorbidities, and their treatment must be chosen with care. For those who are not candidates for intensive chemotherapy, one of the available options for palliative treatment should be chosen on the basis of an individual risk-benefit assessment. METHODS: Selective literature review. RESULTS: An evaluation of the patient's general condition and comorbidities, a geriatric assessment, and specially designed risk scores are useful aids to the choice of an appropriate treatment. Some elderly patients with AML can benefit from intensive chemotherapy despite their age; for highly selected elderly patients, allogeneic stem-cell transplantation is an increasingly feasible option. Hypomethylating agents or low-dose cytarabine can be suitable for some patients. Further options include experimental treatment as part of a clinical trial, and supportive care alone. In the special case of acute promyelocytic leukemia, more than half of all patients can be cured with combination chemotherapy including all-trans retinoic acid. CONCLUSION: The prognosis of elderly AML patients remains poor despite recent therapeutic advances. The appropriate treatment for each patient can be chosen on the basis of a risk-benefit assessment. Clinical trials evaluating new treatments are urgently needed.
BACKGROUND: In patients over age 60 with acute myeloid leukemia (AML), cure rates are under 10% despite intensive chemotherapy. These patients often have comorbidities, and their treatment must be chosen with care. For those who are not candidates for intensive chemotherapy, one of the available options for palliative treatment should be chosen on the basis of an individual risk-benefit assessment. METHODS: Selective literature review. RESULTS: An evaluation of the patient's general condition and comorbidities, a geriatric assessment, and specially designed risk scores are useful aids to the choice of an appropriate treatment. Some elderly patients with AML can benefit from intensive chemotherapy despite their age; for highly selected elderly patients, allogeneic stem-cell transplantation is an increasingly feasible option. Hypomethylating agents or low-dose cytarabine can be suitable for some patients. Further options include experimental treatment as part of a clinical trial, and supportive care alone. In the special case of acute promyelocytic leukemia, more than half of all patients can be cured with combination chemotherapy including all-trans retinoic acid. CONCLUSION: The prognosis of elderly AMLpatients remains poor despite recent therapeutic advances. The appropriate treatment for each patient can be chosen on the basis of a risk-benefit assessment. Clinical trials evaluating new treatments are urgently needed.
Authors: Jan J Cornelissen; Wim L J van Putten; Leo F Verdonck; Matthias Theobald; Emanuel Jacky; Simon M G Daenen; Marinus van Marwijk Kooy; Pierre Wijermans; Harry Schouten; Peter C Huijgens; Hans van der Lelie; Martin Fey; Augustin Ferrant; Johan Maertens; Alois Gratwohl; Bob Lowenberg Journal: Blood Date: 2007-01-09 Impact factor: 22.113
Authors: C Niu; H Yan; T Yu; H P Sun; J X Liu; X S Li; W Wu; F Q Zhang; Y Chen; L Zhou; J M Li; X Y Zeng; R R Yang; M M Yuan; M Y Ren; F Y Gu; Q Cao; B W Gu; X Y Su; G Q Chen; S M Xiong; T D Zhang; S Waxman; Z Y Wang; Z Chen; J Hu; Z X Shen; S J Chen Journal: Blood Date: 1999-11-15 Impact factor: 22.113
Authors: W Y Au; A K W Lie; C S Chim; R Liang; S K Ma; C H Chan; Y K Mak; Y T Chen; C C So; Y M Yeung; S F Yip; L G Wong; J C Chan; S Y Liu; Y L Kwong Journal: Ann Oncol Date: 2003-05 Impact factor: 32.976
Authors: Utz Krug; Christoph Röllig; Anja Koschmieder; Achim Heinecke; Maria Cristina Sauerland; Markus Schaich; Christian Thiede; Michael Kramer; Jan Braess; Karsten Spiekermann; Torsten Haferlach; Claudia Haferlach; Steffen Koschmieder; Christian Rohde; Hubert Serve; Bernhard Wörmann; Wolfgang Hiddemann; Gerhard Ehninger; Wolfgang E Berdel; Thomas Büchner; Carsten Müller-Tidow Journal: Lancet Date: 2010-12-03 Impact factor: 79.321
Authors: Miguel A Sanz; David Grimwade; Martin S Tallman; Bob Lowenberg; Pierre Fenaux; Elihu H Estey; Tomoki Naoe; Eva Lengfelder; Thomas Büchner; Hartmut Döhner; Alan K Burnett; Francesco Lo-Coco Journal: Blood Date: 2008-09-23 Impact factor: 22.113
Authors: Bob Löwenberg; Joachim Beck; Carlos Graux; Wim van Putten; Harry C Schouten; Leo F Verdonck; Augustin Ferrant; Pieter Sonneveld; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Dimitri Breems; Hilde de Muijnck; Ron Schaafsma; Gregor Verhoef; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gert J Ossenkoppele; Johan Maertens Journal: Blood Date: 2010-01-26 Impact factor: 22.113
Authors: Alan K Burnett; Robert K Hills; Donald W Milligan; Anthony H Goldstone; Archibald G Prentice; Mary-Frances McMullin; Andrew Duncombe; Brenda Gibson; Keith Wheatley Journal: J Clin Oncol Date: 2009-12-28 Impact factor: 44.544
Authors: William H Gmeiner; Waldemar Debinski; Carol Milligan; David Caudell; Timothy S Pardee Journal: Future Oncol Date: 2016-06-09 Impact factor: 3.404
Authors: Tamara B Garcia; Jonathan C Snedeker; Dmitry Baturin; Lori Gardner; Susan P Fosmire; Chengjing Zhou; Craig T Jordan; Sujatha Venkataraman; Rajeev Vibhakar; Christopher C Porter Journal: Mol Cancer Ther Date: 2017-06-27 Impact factor: 6.261
Authors: Neha Gupta; Austin Miller; Shipra Gandhi; Laurie A Ford; Carlos E Vigil; Elizabeth A Griffiths; James E Thompson; Meir Wetzler; Eunice S Wang Journal: Am J Hematol Date: 2015-07 Impact factor: 10.047
Authors: Hagop M Kantarjian; Giovanni Martinelli; Elias J Jabbour; Alfonso Quintás-Cardama; Kiyoshi Ando; Jacques-Olivier Bay; Andrew Wei; Stefanie Gröpper; Cristina Papayannidis; Kate Owen; Laura Pike; Nicola Schmitt; Paul K Stockman; Aristoteles Giagounidis Journal: Cancer Date: 2013-04-19 Impact factor: 6.860